Recent News for VRNA - Verona Pharma plc

Date Title
May 13 Verona Pharma plc (VRNA) CEO Jan-Anders Karlsson on Q1 2019 Results - Earnings Call Transcript
May 7 Result of AGM
May 7 Verona Pharma reports Q1 results
May 7 Verona Pharma Initiates Additional Phase 2b Clinical Trial with Nebulized Ensifentrine to Inform Dose Selection for Phase 3 Trials
May 7 Verona Pharma plc Operational Update and Financial Results for the Three Months Ended March 31, 2019
May 3 Key events next week - healthcare
May 2 Verona Pharma to Present Clinical Trial Data of Ensifentrine for COPD Maintenance Treatment at American Thoracic Society 2019 International Conference
May 1 Verona Pharma plc ("Verona" or the "Company") Appointment of Nominated Adviser and UK Broker
May 1 Verona Pharma to Announce Financial Results for First Quarter Ended March 31, 2019 and Provide Clinical Development Update
Apr 25 Verona Pharma to Host Investor & Analyst R&D Forum in London on May 8, 2019
Apr 9 Verona Pharma nabs additional patent in Europe
Apr 9 Verona Pharma Granted Key EU Patent Related to Late-stage COPD Clinical Candidate Ensifentrine
Apr 4 Grant of Options and RSUs and PDMR Dealings
Mar 26 Verona Pharma to Present at H.C. Wainwright Global Life Sciences Conference
Mar 22 2018 Annual Report and Accounts and Notice of AGM 
Mar 21 Dr. Martin Edwards Joins Verona Pharma as Non-Executive Director
Mar 13 Verona Pharma (VRNA) Presents At Cowen and Company 39th Annual Health Care Conference - Slideshow
Mar 7 PDMR Dealing
Mar 4 Verona up 4% on positive ensifentrine data
Mar 4 Verona Pharma Reports Positive Interim Data with Ensifentrine Dry Powder Inhaler Formulation in First of Two-Part Phase 2 Clinical Trial in COPD
Feb 28 The Daily Biotech Pulse: Bristol-Myers Squibb-Celgene Deal Faces Setback, Syneos Hit By SEC Probe, FDA Cheer For T2 Biosystems
Feb 28 Verona Pharma to Present at Cowen and Company 39th Annual Health Care Conference
Feb 27 The Daily Biotech Pulse: FDA Panel Vote Sinks KaryoPharm, Refuse-To-file Letter For Adamis, Tandem Diabetes Earnings
Feb 26 Verona Pharma plc's (VRNA) CEO Jan-Anders Karlsson on Q4 2018 Results - Earnings Call Transcript
Feb 26 Verona Pharma reports FY results

Back to the Main VRNA Page...